Drugs / 18F-Thretide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05516329 | Aug 2022 → Mar 2023 | prostate cancer | First Affiliated Hospital of Fujian Medical University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Thretide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05516329 ↗ |
| Modality | Diagnostic / imaging agent | “This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT” NCT05516329 ↗ |
| Route | Intravenous | “The patients will be intravenously injected with 18F-Thretide” NCT05516329 ↗ |